Skip to main content
HYUNDAI BIOSCIENCE CO., LTD. logo

HYUNDAI BIOSCIENCE CO., LTD. — Investor Relations & Filings

Ticker · 048410 ISIN · KR7048410005 KO Professional, scientific and technical activities
Open in API
Filings indexed 288 across all filing types
Latest filing 2024-03-11 M&A Activity
Country KR South Korea
Listing KO 048410

About HYUNDAI BIOSCIENCE CO., LTD.

http://www.hyundaibioscience.com/eindex…

HYUNDAI BIOSCIENCE CO., LTD. is a biotechnology company focused on developing innovative therapeutics using its proprietary drug delivery system (DDS) technology. The company's core science is based on organic-inorganic hybrid technologies designed to safely and effectively deliver active ingredients. Its main development pipeline includes CP-COV03, a broad-spectrum antiviral agent that enhances cellular autophagy to combat viral infections, and Polytaxel, an anticancer drug candidate developed with polymer transfer technologies to reduce toxicity. The company's primary focus is on creating novel treatments for viral diseases and cancer.

Recent filings

Filing Released Lang Actions
주요사항보고서(타법인주식및출자증권양수결정)
M&A Activity Classification · 100% confidence The document is a 'Major Report' (주요사항보고서) filed with the Financial Supervisory Service and Korea Exchange by Hyundai Bioscience. It details the acquisition of shares in another company (에이디엠코리아 주식회사) to secure management control. This type of regulatory filing regarding M&A activity, share acquisition, and corporate restructuring falls under the M&A Activity category.
2024-03-11 Korean
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a formal regulatory filing titled '감사보고서 제출' (Submission of Audit Report) submitted by Hyundai Bioscience. It contains the auditor's opinion, financial statements (consolidated and separate), and key financial metrics required by regulatory authorities upon the completion of an audit. While it provides financial data, it is a specific regulatory disclosure of the audit results rather than a full Annual Report (10-K) or a simple announcement of publication (RPA). Given the structure and content, it falls under the category of Audit Report / Information. FY 2023
2024-03-06 Korean
사업보고서 (2023.12)
Audit Report / Information Classification · 100% confidence The document is a formal 'Audit Report' (감사보고서) for Hyundai Bioscience Co., Ltd. for the fiscal year ending December 31, 2023. It includes the independent auditor's opinion, financial statements (Statement of Financial Position, Comprehensive Income Statement, Statement of Changes in Equity, Statement of Cash Flows), and detailed notes to the financial statements. While it contains financial data, it is the official audit report rather than a standalone annual report (10-K) or a simple earnings release. Given the specific nature of the document as an audit report, it falls under the 'AR' category. FY 2023
2024-03-06 Korean
[기재정정]주주총회소집공고
AGM Information Classification · 100% confidence The document is a 'Notice of Convocation of General Meeting of Shareholders' (주주총회소집공고) for Hyundai Bioscience. It includes the agenda for the upcoming Annual General Meeting (AGM), such as the approval of financial statements, appointment of auditors, and director compensation. While it contains financial data, this data is provided as 'management reference material' (경영참고사항) specifically for the purpose of the shareholder meeting, not as a standalone annual report or earnings release. Therefore, it is classified as AGM-related materials.
2024-02-28 Korean
[기재정정]의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a 'Proxy Solicitation & Information Statement' (의결권대리행사권유참고서류) filed by Hyundai Bioscience. It contains detailed information regarding the upcoming Annual General Meeting (AGM), including agenda items (financial statement approval, director/auditor appointments, compensation limits, and stock option grants), voting procedures, and proxy solicitation details. This aligns perfectly with the definition of a Proxy Solicitation & Information Statement (PSI).
2024-02-28 Korean
주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) for Hyundai Bioscience. It outlines the date, location, and agenda items (such as financial statement approval, auditor appointment, and remuneration limits). This document serves as the official notification and proxy-related information sent to shareholders to inform them of the upcoming meeting and the matters to be voted upon. According to the provided definitions, this fits the Proxy Solicitation & Information Statement (PSI) category.
2024-02-27 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.